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Abstract
Background: Relapse of major depressive disorder (MDD) is a common clinical problem. This study was designed
to determine whether residual sleep disturbance (insomnia and hypersomnia) predict risk of relapse during the
continuation and maintenance treatment of MDD.
Methods: A total of 570 patients with MDD were treated with open-label, flexible dose fluoxetine (range 20 to
60 mg; mean dose = 45.8 mg/day; SD = 15.1) for 12 weeks. Under double blind conditions, 262 patients who
achieved clinical response were randomly assigned to continue fluoxetine or to switch to placebo for 52 weeks or
until relapse. Residual sleep disturbance during the baseline visit of the double-blind phase was assessed using
items 4, 5, 6 (insomnia) and 22, 23, 24 (hypersomnia) of the Hamilton Depression Rating Scale (HDRS). Survival
analysis was utilized to determine the effect of residual sleep disturbance on risk of relapse.
Results: The severities of early (P > 0.05), middle (P > 0.05), late (P > 0.05), or total (P > 0.05) residual insomnia
were not found to significantly predict risk of relapse during continuation and maintenance-phase treatment.
Similarly, the severities of early bedtime (P > 0.05), oversleeping (P > 0.05), napping (P > 0.05), or total (P > 0.05)
residual hypersomnia were not found to significantly predict risk of relapse during continuation and maintenance-
phase treatment.
Conclusion: The present study did not identify the severity of residual sleep disturbance among fluoxetine
responders to predict risk of MDD relapse. The size of our sample may have precluded us from identifying more
modest effects of residual sleep disturbance on the risk of relapse in MDD patients. Future studies are needed to
further explore the relationship between residual sleep disturbance and relapse in MDD.
Trial Registration: ClinicalTrials.gov Identifier: NCT00427128
Background
Major depressive disorder (MDD) is a prevalent and,
often recurrent illness that is associated with significant
disability, morbidity, and mortality. MDD, according to
the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition (DSM-IV) [1,2], is diagnosed by the
presence of a constellation of symptoms including psy-
chological (that is, sadness), behavioral (that is, suicidal
gestures), cognitive (that is, concentration), and somatic/
physical symptoms (that is, sleep, energy, psychomotor,
and appetite disturbances). However, whether all depres-
sive symptoms weigh equally with regards to their
adverse impact on functioning, morbidity, mortality, and
treatment outcome or whether some symptoms are
more relevant than others remains, as of yet, undeter-
mined. Furthermore, although the goal of treating MDD
is to achieve full remission, it is common for many
patients to continue suffering from residual symptoms
after they respond to treatment [3]. Increasingly,
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tance of treating residual symptoms and of exploring
their neurobiological basis to develop better treatment
options and to improve MDD outcome [4].
Several studies published to date suggest that sleep
disturbance, namely insomnia and hypersomnia, may
represent such symptoms that weigh more heavily with
regards to their adverse impact on a number of out-
comes. Specifically, a number of studies report an
increased risk of subsequently developing MDD among
non-depressed individuals complaining of insomnia
(that is, insomnia may represent a prodromal symptom)
[5,6]. Similarly, Roberts et al. [7] found that non-
depressed individuals experiencing hypersomnia were at
increased risk for developing MDD later on than indivi-
duals without hypersomnia. In addition, studies have
established a positive correlation between the presence
of sleep disturbance, including hypersomnia and insom-
nia, and a greater severity of depressive and anxiety
symptoms [8,9], as well as increased suicide rates
[10-12] among depressed patients. In addition, insomnia
and hypersomnia appear to be among the most com-
mon residual symptoms following selective serotonin
reuptake inhibitor (SSRI) treatment [13-15] and, often,
require the use of specialized therapeutic interventions
above and beyond the use of antidepressant monother-
apy to ensure their full resolution [16-26]. Most impor-
tantly, there is preliminary evidence to suggest that
residual sleep disturbance at remission may be especially
deleterious with regards to its potential adverse impact
on relapse/recurrence in MDD. Dombrovski and collea-
gues [27], for instance, used data from a clinical trial of
maintenance treatment of late-life depression to analyze
the impact of overall residual symptom levels as well as
specific residual depressive symptom clusters on depres-
sive recurrence. Both residual anxiety and residual sleep
disturbance were found to be significant independent
predictors of early recurrence across treatment groups.
Identifying predictors of relapse in MDD is potentially
clinically relevant, since such predictors could lead to
the development of specialized treatment interventions
which could reduce the risk of relapse/recurrence in
MDD. Despite the encouraging results reported in the
work by Dombrovski et al. [27], some studies have had
different findings. For example, one Sequenced Treat-
ment Alternatives to Relieve Depression (STAR*D)
report [28] suggests that the association between resi-
dual sleep disturbance and MDD recurrence is far from
being fully understood. For this reason, there is the
need for more studies specifically examining the role of
residual sleep disturbance as a predictor of relapse in
MDD.
Therefore, the purpose of the present study was to
explore the impact of residual sleep disturbance on the
risk of relapse of MDD during the continuation/mainte-
nance treatment with the SSRI fluoxetine among fluoxe-
tine responders. In order to achieve this, we reanalyzed
data from a 52-week, randomized, double-blind, pla-
cebo-controlled trial of fluoxetine continuation/mainte-
nance treatment for MDD patients who had responded
following a 12-week, open-label, flexible dose trial of
fluoxetine. The original trial was specifically designed to
identify predictors of relapse during the continuation/
maintenance phase of MDD [29].
Methods
The present work is a post hoc analysis of data from a
clinical trial of fluoxetine in MDD [29]. For that trial,
627 patients, 18 to 65 years of age, with current MDD
d e f i n e du s i n gD S M - I Vc r i t e r i aw e r er e c r u i t e da to n eo f
two sites: either the New York State Psychiatric Institute
in New York City, NY, USA (n = 372) or the Depression
Clinical and Research Program of the Massachusetts
General Hospital in Boston, MA, USA (n = 254). Insti-
tutional review boards at both sites approved the study,
and all participants provided written informed consent.
D i a g n o s e sw e r em a d eu s i n gt h eS t r u c t u r e dC l i n i c a l
Interview for DSM-IV Axis I Disorders, Patient Edition
(SCID-PE) [2] with no minimum score for severity of
depressive symptoms required for inclusion in the study.
Medical screening was performed, including medical
history, physical examination, electrocardiogram (ECG),
complete blood count (CBC), blood chemistry profile,
thyroid function tests, urinalysis, and urine drug screen.
Patients were excluded from the study if they were at
significant risk of suicide; were pregnant or breastfeed-
ing, were women not using effective contraception; had
an unstable physical disorder; had a lifetime history of
any organic mental disorder, psychotic disorder, or
mania; had a history of seizures; had a neurological dis-
order that significantly affects central nervous system
(CNS) function; had met criteria for substance abuse or
dependence in the previous 6 months, other than nico-
tine dependence; were taking medications that may
cause or exacerbate depression; had clinical or labora-
tory evidence of hypothyroidism without adequate and
stable replacement therapy; or had a history of non-
response to an adequate trial of a SSRI (defined as a 4-
week trial of ≥ 40 mg of fluoxetine or the equivalent
daily).
After a 1-week medication-free washout period,
patients (n = 570) who continued to meet inclusion
criteria and whose symptoms had not improved signifi-
cantly (Clinical Global Impressions-Improvement
(CGI-I) score >2) began a 12-week course of open-label
treatment with fluoxetine. Patients were evaluated by a
research psychiatrist weekly during the first 6 weeks,
biweekly for the next 4 weeks, and weekly for the final
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Page 2 of 52 weeks. Target fluoxetine dosages were 10 mg/day for
the first week, 20 mg/day for weeks 2 to 4, 40 mg/day
for weeks 4 to 8, and 60 mg/day for weeks 5 to 12. The
dose was increased to meet the target only if the patient
tolerated the medication well, and it was increased to 40
mg daily for all patients who could tolerate it. Treat-
ment response during the acute phase was defined as a
CGI-I [30] scale score less than 3 for the last two visits
of the open-label phase and no longer meeting DSM-IV
criteria for MDD (by SCID-PE).
Patients who responded to the medication by week 12
(n = 262) entered a discontinuation phase during which
they underwent random assignment, under double-blind
conditions with computer-generated randomization,
either to continue taking fluoxetine (n = 131) at the
dose to which they had responded or to switch to pla-
cebo (n = 131) for 52 weeks or until relapse. Patients
were seen monthly for the duration of the 52-week trial.
By convention, the first 6 months of this period were
considered the continuation phase, and the remainder,
the maintenance phase. Identical fluoxetine or placebo
capsules were dispensed by a research pharmacist. Com-
pliance was monitored by counting returned capsules;
participants whose adherence to the protocol was judged
inadequate by the treating research psychiatrist were
removed from the study. Relapse during the double-
blind discontinuation phase was defined as having at
least 2 consecutive weeks of ratings of less than ‘much
improved’ on the CGI-I compared with ratings at entry
into the study.
Residual sleep disturbance measure
The Hamilton Depression Rating Scale (HDRS) [31]
administered during the randomization visit (baseline
visit of the continuation and maintenance phase of the
study) was used to assess residual sleep disturbance.
Specifically, HDRS items 4 (early insomnia, that is diffi-
culty falling asleep), 5 (middle insomnia, that is awaken-
ings during night-time), 6 (late insomnia, that is early
morning awakenings) were utilized, 22 (early bedtime,
that is falling asleep earlier than usual), 23 (oversleeping,
that is waking up later than usual in the morning), and
24 (napping, that is daytime napping) were utilized.
Each item is scored as 0, 1, or 2.
Statistical tests
In order to test whether the presence of residual sleep
disturbance predicted an increased risk of MDD relapse,
we conducted a survival analysis (Cox proportional
hazards regression), using SPSS 16.0 (SPSS Inc., Chi-
cago, IL, USA), with time to relapse as the dependent
variable and the following independent variables (1) the
17-item HDRS (HDRS-17) total score during the rando-
mization visit (week 12), (2) gender, (3) chronicity (as
defined in McGrath et al. [29]), (4) and each individual
insomnia item score, each individual hypersomnia item
score, total insomnia burden (the sum of items 4, 5, and
6), or total hypersomnia burden (the sum of items 22,
23, and 24) entered separately. Gender and chronicity
were added to the model since they were found to pre-
dict risk of relapse (not differential by treatment) in the
original study [29]. Two-sided statistical tests were
employed, with alpha set at the 0.05 level of significance.
Results
T h er e s u l t so ft h eo r i g i n a ls t u d ya r er e p o r t e de l s e w h e r e
[29]. Briefly, the participants who underwent random
assignment were a mean age of 38.2 years (SD = 10.9),
and 55.3% were female. Their mean HDRS score was
17.1 (SD = 4.1) at baseline and 4.9 (SD = 3.1) at rando-
mization; 22.7% of them had a history of dysthymia and
thus currently had ‘double depression’. About two-thirds
(35%) of the participants had one or more comorbid
axis I disorder, most commonly panic disorder (13.3%),
social phobia (12.4%), and alcohol dependence (10.6%).
During this phase, 85 participants left the study, on
average 16.4 weeks (SD = 2.0) after randomization; 34
of them were from the placebo group (26.0% of the pla-
cebo group), and 51 were from the fluoxetine group
(38.9%). The most common reasons for leaving during
this phase were removal for inadequate adherence
(30.6% of those who left the study), loss to follow-up
(14.1%), and side effects (7.1%). Fluoxetine treatment
during continuation and maintenance treatment was
associated with continued remission (ratio of relapse
hazard during placebo substitution to relapse hazard
during fluoxetine continuation = 1.73; 95% CI 1.20 to
2.51). The relapse rates at the end of the continuation
phase (6 months after randomization) were 35.2% for
the fluoxetine group and 61.8% for the placebo group;
after 1 year, they were 45.9% for the fluoxetine group
and 72.0% for the placebo group.
Mean (SD) residual insomnia scores among during the
baseline visit of the double-blind phase were as follows:
early insomnia 0.46 (0.77), middle insomnia 0.54 (0.75),
late insomnia 0.50 (0.74), total insomnia 1.50 (1.68).
Mean (SD) severity of residual hypersomnia scores
among during the baseline visit of the double-blind
phase were as follows: early bedtime 0.16 (0.45), over-
sleeping 0.22 (0.49), daytime napping 0.34 (0.59), total
hypersomnia 0.71 (1.00).
The severities of early (hazard ratio = 0.80; P = 0.19),
middle (hazard ratio = 1.00; P = 0.99), late (hazard ratio
=0 . 9 9 ;P = 0.95), and total insomnia (hazard ratio =
0.95; P = 0.53) were not found to predict risk of relapse.
Similarly, the severities of early bedtime (hazard ratio =
1.19; P = 0.44), oversleeping (hazard ratio = 1.23; P =
0.30), daytime napping (hazard ratio = 1.10; P =0 . 5 2 ) ,
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were not found to predict risk of relapse.
Conclusions
The present study is the first to specifically focus on test-
ing the effects of residual sleep disturbance, including
insomnia and hypersomnia, as a predictor of relapse dur-
ing the continuation and maintenance treatment of MDD
with the SSRI fluoxetine or placebo. In addition, although
several studies have explored the relationship between
clinical presentation during recovery from a major depres-
sive episode and the risk of subsequent relapse, the present
study is the first to be specifically designed to identify
predictors of relapse in MDD. In summary, the results of
the present analysis do not suggest that a greater burden
of residual sleep disturbance is associated with a higher
risk of relapse among fluoxetine responders with MDD
during the continuation/maintenance phase of treatment
with either fluoxetine or placebo.
While the above findings are quite interesting, several
limitations to this study need to be considered in inter-
preting the results. Clinical trials, including the present
one, typically involve a number of inclusion and exclu-
sion criteria, and it is therefore not possible to extend
findings from clinical trials to patient populations typi-
cally excluded form clinical trials (that is, patients who
are actively suicidal, with psychotic symptoms, with
uncontrolled medical illness, or with bipolar disorder).
In addition, although the present trial did not identify a
robust relationship between residual sleep disturbance
and time to depressive relapse, it may have been under-
powered to identify weaker effects of such residual
symptoms on long-term treatment outcome. Therefore,
the present results are, merely, preliminary/suggestive
and need to be confirmed by future studies. Finally, the
present study did not employ a second, ‘active’ treat-
ment arm. It would have been interesting to explore
whether or not a similar relationship between specific
residual insomnia and risk of relapse would also hold
for antidepressants that employ a different mechanism
of action. In addition, the dependence of MDD residual
symptoms on other factors such as caffeine intake and
diurnal variation of depressive symptoms (such data was
not available from the original study for us to analyze)
would be interesting to include in future research. Ulti-
mately, the exploration of neurobiological markers of
MDD including residual symptoms will be essential to
advance our knowledge of this disabling condition,
which will lead to the development of new diagnostic
classification, treatment and prevention.
In conclusion, the present study did not identify the
severity of residual sleep disturbance among fluoxetine
responders to predict a higher risk of MDD relapse. The
size of our sample may have precluded us from identify-
ing more modest effects of residual sleep disturbance on
t h er i s ko fr e l a p s ei nM D Dp a t i e n t s .F u t u r es t u d i e sa r e
needed to further explore the relationship between resi-
dual sleep disturbance and relapse in MDD.
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